EMA to Support Small and Medium-Sized Enterprises

Article

The agency published an action plan to nurture innovation and drug development by SMEs.

On May 31, 2017, the European Medicines Agency (EMA) announced an action plan to help small and medium-sized enterprises (SMEs) develop novel human and veterinary medicines. The plan is based on the experience of the EMA’s SME Office and will provide training and other support to SMEs.

Specifically, the plan will include spreading awareness of the agency’s initiative by engagement with pharmaceutical players including incubators, universities, and investors. It will offer training that includes an expanded EU Network Training Center. It also supports action to maximize the use of regulatory tools for the development of treatments for unmet needs. The plan will also foster the development of the EU Innovation Network, SME support initiatives, and additional support for SMEs in regards to funding and administration. According to EMA, SMEs make up 99% of all businesses in the European Union and play an important role in the development of new drugs.

More on EMA’s SME initiatives can be found in the SME Office’s annual report.

Source: EMA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content
© 2025 MJH Life Sciences

All rights reserved.